Interest and Utility of MC1R Testing for Melanoma Risk in Dermatology Patients with a History of Nonmelanoma Skin Cancer
Public access to genetic information is increasing, and community dermatologists may progressively encounter patients interested in genetic testing for melanoma risk. Clarifying potential utility will help plan for this inevitability. We determined interest and uptake of genetic risk feedback based...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Skin Cancer |
| Online Access: | http://dx.doi.org/10.1155/2022/4046554 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850177120578306048 |
|---|---|
| author | Jennifer L. Hay Erica H. Lee Stephanie N. Christian Elizabeth Schofield Jada G. Hamilton Ciyu Yang Bobak Hedayati Keimya Sadeghi Mark E. Robson Allan Halpern Liying Zhang Irene Orlow |
| author_facet | Jennifer L. Hay Erica H. Lee Stephanie N. Christian Elizabeth Schofield Jada G. Hamilton Ciyu Yang Bobak Hedayati Keimya Sadeghi Mark E. Robson Allan Halpern Liying Zhang Irene Orlow |
| author_sort | Jennifer L. Hay |
| collection | DOAJ |
| description | Public access to genetic information is increasing, and community dermatologists may progressively encounter patients interested in genetic testing for melanoma risk. Clarifying potential utility will help plan for this inevitability. We determined interest and uptake of genetic risk feedback based on melanocortin receptor gene (MC1R) variants, immediate (two weeks) responses to risk feedback, and test utility at three months in patients (age ≥ 18, with a history of nonmelanoma skin cancer). Participants (N = 50) completed a baseline survey and were invited to consider MC1R testing via the study website. Testing interest and uptake were assessed through registration of test decision, request of a saliva test kit, and kit return (all yes/no). Immediate responses to risk feedback included feedback-relevant thoughts, emotions, communication, and information seeking after result receipt; test utility outcomes included family and physician communication and information seeking. Results indicated good retention at both time points (76%; 74%). Half (48%) logged onto the study website, and of these, most (92%) chose testing and (95%) returned a saliva sample. After two weeks, most (94%) had read all the risk feedback information and distress was low (M = 8.81, 7–28, SD = 2.23). Many (69%) had talked with their family about the results. By three months, most had spoken with family (92%) and physicians (80%) about skin cancer risk. Physician communication was higher (70%) in those tested versus those not tested (40%, p=0.02). The substantial interest and promising outcomes associated with MC1R genetic testing in dermatology patients inform intervention strategies to enhance benefits and minimize risks of skin cancer genetic testing. |
| format | Article |
| id | doaj-art-ae40dd67f0a2412bbfbd0d680e049af8 |
| institution | OA Journals |
| issn | 2090-2913 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Skin Cancer |
| spelling | doaj-art-ae40dd67f0a2412bbfbd0d680e049af82025-08-20T02:19:05ZengWileyJournal of Skin Cancer2090-29132022-01-01202210.1155/2022/4046554Interest and Utility of MC1R Testing for Melanoma Risk in Dermatology Patients with a History of Nonmelanoma Skin CancerJennifer L. Hay0Erica H. Lee1Stephanie N. Christian2Elizabeth Schofield3Jada G. Hamilton4Ciyu Yang5Bobak Hedayati6Keimya Sadeghi7Mark E. Robson8Allan Halpern9Liying Zhang10Irene Orlow11Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer CenterUniversity of PittsburghMemorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer CenterUniversity of CaliforniaMemorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer CenterUniversity of CaliforniaMemorial Sloan Kettering Cancer CenterPublic access to genetic information is increasing, and community dermatologists may progressively encounter patients interested in genetic testing for melanoma risk. Clarifying potential utility will help plan for this inevitability. We determined interest and uptake of genetic risk feedback based on melanocortin receptor gene (MC1R) variants, immediate (two weeks) responses to risk feedback, and test utility at three months in patients (age ≥ 18, with a history of nonmelanoma skin cancer). Participants (N = 50) completed a baseline survey and were invited to consider MC1R testing via the study website. Testing interest and uptake were assessed through registration of test decision, request of a saliva test kit, and kit return (all yes/no). Immediate responses to risk feedback included feedback-relevant thoughts, emotions, communication, and information seeking after result receipt; test utility outcomes included family and physician communication and information seeking. Results indicated good retention at both time points (76%; 74%). Half (48%) logged onto the study website, and of these, most (92%) chose testing and (95%) returned a saliva sample. After two weeks, most (94%) had read all the risk feedback information and distress was low (M = 8.81, 7–28, SD = 2.23). Many (69%) had talked with their family about the results. By three months, most had spoken with family (92%) and physicians (80%) about skin cancer risk. Physician communication was higher (70%) in those tested versus those not tested (40%, p=0.02). The substantial interest and promising outcomes associated with MC1R genetic testing in dermatology patients inform intervention strategies to enhance benefits and minimize risks of skin cancer genetic testing.http://dx.doi.org/10.1155/2022/4046554 |
| spellingShingle | Jennifer L. Hay Erica H. Lee Stephanie N. Christian Elizabeth Schofield Jada G. Hamilton Ciyu Yang Bobak Hedayati Keimya Sadeghi Mark E. Robson Allan Halpern Liying Zhang Irene Orlow Interest and Utility of MC1R Testing for Melanoma Risk in Dermatology Patients with a History of Nonmelanoma Skin Cancer Journal of Skin Cancer |
| title | Interest and Utility of MC1R Testing for Melanoma Risk in Dermatology Patients with a History of Nonmelanoma Skin Cancer |
| title_full | Interest and Utility of MC1R Testing for Melanoma Risk in Dermatology Patients with a History of Nonmelanoma Skin Cancer |
| title_fullStr | Interest and Utility of MC1R Testing for Melanoma Risk in Dermatology Patients with a History of Nonmelanoma Skin Cancer |
| title_full_unstemmed | Interest and Utility of MC1R Testing for Melanoma Risk in Dermatology Patients with a History of Nonmelanoma Skin Cancer |
| title_short | Interest and Utility of MC1R Testing for Melanoma Risk in Dermatology Patients with a History of Nonmelanoma Skin Cancer |
| title_sort | interest and utility of mc1r testing for melanoma risk in dermatology patients with a history of nonmelanoma skin cancer |
| url | http://dx.doi.org/10.1155/2022/4046554 |
| work_keys_str_mv | AT jenniferlhay interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT ericahlee interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT stephanienchristian interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT elizabethschofield interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT jadaghamilton interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT ciyuyang interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT bobakhedayati interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT keimyasadeghi interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT markerobson interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT allanhalpern interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT liyingzhang interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer AT ireneorlow interestandutilityofmc1rtestingformelanomariskindermatologypatientswithahistoryofnonmelanomaskincancer |